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Jun Li1*, Yong-Qin Liu1 and Han-Ting Zhang2*Abstract
Rocuronium and vecuronium, two non-depolarizing neuromuscular blockers, have been widely used in surgery
procedures. However, their electrophysiological properties need to be more widely explored. We examined the
effects of rocuronium and vecuronium on initial rundown of endplate potential amplitudes in the non-uniform
stretched muscle preparation of the rat isolated phrenic nerve diaphragm. More specifically, the endplate potentials
were recorded with one microelectrode from a single endplate. The effects of rocuronium or vecuronium each at 4
concentrations (0.5 ×, l ×, 2 ×, 4 × EC95; EC95 = concentration of the drug required to produce the inhibitory effect
by 95%) on the amplitude of endplate potentials and its rundown were observed. Treatment of the isolated rat
phrenic nerve-diaphragm preparation with rocuronium (2.5–20 μg/ml) or vecuronium (0.5–4 μg/ml) decreased the
amplitude of endplate potentials and inhibited its rundown in a concentration-dependent manner. At the
concentration (2.5 μg/ml for rocuronium and 0.5 μg/ml for vecuronium) that did not alter the endplate potential
amplitude, the onset of reduced endplate potential rundown was 3 and 5 min after administration of rocuronium
or vecuronium, respectively. The results suggest that rocuronium and vecuronium block the neuromuscular
junction presynaptically and that rocuronium does it faster than vecuronium.
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The isolated phrenic nerve diaphragm preparation is the
most frequently used model for studying electric neuro-
transmission of the neuromuscular junction, which is one
of the most widely studied synapses. The junction consists
of three distinct parts: the presynaptic part, which is the
distal nerve terminal, the synaptic cleft, and the postsyn-
aptic part, which is a part of the muscle membrane
(Fagerlund & Eriksson 2009). Acetylcholine (ACh) is the
primary neurotransmitter that is synthesized, stored and
released by the nerve terminal. The transmission from
nerve to muscle is completed via the release of ACh from
presynapses and activation of ligand-gated, fast-acting nic-
otinic ACh receptors (nAChRs) on postsynapses.
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in any medium, provided the original work is phave been widely used in surgical procedures. While both
drugs are monoquaternary aminosteroids and share a
similar structure, rocuronium is much less potent, with
the ED95 of 0.36 mg/kg, compared to the ED95 of
0.05 mg/kg for vecuronium (Foldes et al. 1991; Xue et al.
1998). The lack of potency is considered to be an import-
ant factor in determining the onset of neuromuscular
blocking (Bowman et al. 1988). Agents with less potency
are more likely to achieve a rapid onset of action.
Rocuronium produces the maximum effect within 2 min,
which is much more rapid than any other non-
depolarizing relaxant (Bevan 1994; Nava-Ocampo et al.
2006). As for rocuronium, nearly all neuromuscular
blocking molecules are bound to the postsynaptic nAChRs
at the neuromuscular junction. Rocuronium also binds to
the presynaptic N-cholinergic receptor at the neuromus-
cular junction (Meistelman et al. 1992), leading to pre-
synaptic inhibition (Schwarz et al. 1985). This is thought
to contribute to the rapid onset of rocuronium’s action
(Feldman & Hood 1994). However, electrophysiologicalen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Li et al. SpringerPlus 2013, 2:155 Page 2 of 6
http://www.springerplus.com/content/2/1/155evidence is still lacking for the pharmacological properties
of non-depolarizing neuromuscular blockers with rapid on-
set of actions. In the present study, we aimed to compare
the effects of rocuronium and vecuronium on initial run-
down of the amplitude of endplate potentials (EPPs) in the
non-uniform stretched muscle preparation of the isolated
rat phrenic nerve diaphragm, in order to determine the in-
hibitory effect of both drugs on presynaptic transmission.
Methods
Male and female adult Wistar rats (the Animal Center of
the Academy of Military Medical Sciences, Beijing,
China), weighing 160–220 g, were used for the experi-
ments. The left side of the diaphragm with the phrenic
nerve was dissected from the rat following the proce-
dures described previously (Bulbring 1997). The phrenic
nerve diaphragm was kept in the Tyrode's solution with
95% O2 and 5% CO2. The shear diaphragm (2 × 2 cm)
was prepared and made into the non-uniform stretched
muscle preparation. Samples were placed in the water
bath, which was placed on the working platform within
the network mask. The phrenic nerve was put in the
hook of the stimulated electrodes; the distance between
the electrodes was 1 mm. Phrenic nerves were stimulated
with 8 V super square wave stimulation with pulse width
of 10–20 μs via the SEN-3201 stimulator connected to the
SS-102 J Isolator (NihonKohden Corporation, Japan). The
position of the diaphragm with very slight contraction was
located and the motor endplates around the nerve fibers
stretching into the diaphragm were identified using the
dissecting microscope. All the animal experiments were
performed following the procedures approved by the
Animal Care and Use Committee of the Academy of
Military Medical Sciences, Beijing, China, and the National
Institute of Health Guide for the Care and Use of Labora-
tory Animals (NIH Publications No. 80-23, revised 1996).
Signals were outputted from the 10-Vm connector of
the amplifier to the VC-10 oscilloscope (NihonKohden
Corporation, Japan) (average voltage height = 10). Resting
membrane potential was shown in the amplifier Vm. The
miniature EPP (MEPP) and EPP, which were amplified
using the VC-10 AC (sensitivity 10 mV/cm) and DC amp-
lification (sensitivity 0.1 V/cm), respectively, were output-
ted and stored in the DTC-75ES tape recorder (Nihon
Kohden Corporation, Japan). The signals were collected
and saved in the computer from the ISC-67 module (A/D;
16-channel, 12-bit, 1 μs) converting board (RC Electronics
Corporation, USA), with the collecting frequency 10 ~
20 kHz. Signal acquisition and analysis were performed
using the Computerscope-PHY system (RC Electronics
Corporation, USA).
Rocuronium and vecuronium (N.V. Organon, Oss,
The Netherlands) were diluted with the Tyrode's solu-
tion. The effects of rocuronium and vecuronium at theconcentrations of 0.5 ×, l ×, 2 ×, 4 × EC95 (EC95 = con-
centration of the drug required to produce the inhibitory
effect by 95%) on the EPP amplitude and its initial run-
down (i.e., the decrease in the size of the EPP) were ex-
amined and compared with the vehicle (the Tyrode’s
solution) control. More specifically, each drug was tested
in the following groups of concentrations: 0 (vehicle
control), 2.5, 5, 10, and 20 μg/ml for rocuronium and 0,
0.5, 1, 2, and 4 μg/ml for vecuronium. All the drug con-
centrations were identified as the final concentrations in
the 20-ml bath. The data was recorded at three time
points for each drug after administration, i.e., 1, 3, and
5 min after rocuronium and 3, 5, and 10 min after
vecuronium. The concentrations and time points were de-
termined based on our preliminary study and studies pub-
lished elsewhere, which demonstrate that rocuronium is
less potent and has about a half of the onset time relative
to vecuronium (Xue et al. 1998; Chatrath et al. 2010). The
rundown rate is the percentage of the difference between
the first quantum content of EPP and the 11–55 average
quantum content of EPP divided by the first quantum
content of EPP in the trains of EPPs. Data collected and
analyzed by the Computerscope-PHY were graphed using
Origin 2.94.
Data analysis
All values are expressed as means ± SEM. The data were
analyzed using one-way analysis of variance (ANOVA)
followed by post hoc Student’s t tests. P < 0.05 was con-
sidered statistically significant.
Results
Normal EPPs and trains of EPPs are shown in Figure 1A.
The EPP amplitudes were not different among the concen-
tration groups before treatment with rocuronium or
vecuronium (Tables 1 and 2), suggesting similar EPP base-
lines before drug treatment. Rocuronium (2.5–20 μg/ml)
decreased the amplitude of EPPs in the non-uniform
stretched muscle preparation in a concentration-dependent
manner. Specifically, while rocuronium at 2.5 μg/ml did
not affect the EPP amplitude, it reduced the EPP amplitude
at the concentration of 5 μg/ml at 3 and 5 min after
drug administration (P < 0.05 and P < 0.01, respectively);
at higher concentrations of 10 and 20 μg/ml, rocu-
ronium decreased the EPP amplitude at all the three
time points (i.e., 1, 3, and 5 min after drug administra-
tion; P < 0.05 or P < 0.01; Table 1).
Similar to rocuronium, vecuronium at 0.5–4 μg/ml
also decreased the EPP amplitude in the non-uniform
stretched muscle preparation in a concentration-dependent
manner. More specifically, while vecuronium at 0.5 μg/ml
did not affect the EPP amplitude compared to the
control, it reduced the EPP amplitude at 1 μg/ml at 5
and 10 min after drug administration (P < 0.05 and
Figure 1 Effects of rocuronium and vecuronium on the rundown rate of trains of endplate potentials (EPPs) in the isolated phrenic
nerve diaphragm preparation of rats. (A) Examples of the single normal EPP (a) and trains of EPPs (b) in the isolated phrenic nerve diaphragm
preparation. The second wave of the normal EPP was higher than the first wave (a). In the trains of EPPs (b), the amplitude of EPP1 was 32.4 mV; the
average amplitude of EPP11-50 was 27.8 mV; the decay rate (R) = [1−(EPP11-50 average quantum content/EPP1 quantum content)] × 100%= 74%.
n = 2 (a) or 50 (b). (B) The effect of rocuronium (2.5 μg/ml) on the rundown rate of trains of EPPs at 3 min after drug administration. (a) Normal control;
(b) post-treatment of rocuronium. (C) The effect of vecuronium (0.5 μg/ml) on the rundown rate of trains of EPPs at 5 min after drug administration.
(a) Normal control; (b) post-treatment of vecuronium.
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trations of 2 and 4 μg/ml, vecuronium decreased the
EPP amplitude at all the three time points (i.e., 3, 5,
and 10 min after drug administration (P < 0.05 or
P < 0.01).To compare the onset and potency of the actions, we
examined the rundown rates of EPP amplitudes at 3 and
5 min after treatment with rocuronium or vecuronium,
each at the concentration that did not alter the EPP ampli-
tude (i.e., 2.5 μg/ml for rocuronium and 0.5 μg/ml for
Table 1 Effects of rocuronium on the amplitude of endplate potentials (EPPs) in the isolated rat phrenic nerve






EPP (mV) at different times after treatment
1 min 3 min 5 min
Control 32.4 ± 3.3 32.2 ± 3.4 32.2 ± 3.3 31.4 ± 3.5
2.5 32.6 ± 3.6 32.3 ± 3.4 32.1 ± 3.5 31.2 ± 3.3
5.0 33.5 ± 3.4 32.4 ± 3.3 22.4 ± 2.9*# 14.6 ± 2.1**##
10.0 34.8 ± 4.3 27.2 ± 2.5** 16.4 ± 1.3**## 12.4 ± 1.3**##
20.0 33.2 ± 3.1 22.4 ± 2.3*# 12.4 ± 2.3*# 9.4 ± 1.1**##
* P < 0.05, ** P < 0.01, compared with the corresponding group without rocuronium; # P < 0.05, ## P < 0.01, compared with the control at the same time point; n = 5.
Data shown are means ± SEM.
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concentration decreased initial rundown rates of EPP trains.
Rocuronium had slightly greater efficacy at 2.5 μg/ml 3 min
after administration relative to vecuronium at 0.5 μg/ml
5 min after administration (Figure 1B, C). In addition, com-
pared to vecuronium, rocuronium generated trains of EPP
rundown earlier, while the potency is smaller (2.5 μg/ml vs.
0.5 μg/ml required respectively to generate the maximum
effect; Table 3).
Discussion
The neuromuscular junction is a typical class of peripheral
cholinergic synapses. Under normal circumstances, nerve
stimulation produces presynaptic release of a large num-
ber of ACh, leading to a postsynaptic endplate potential
and a subsequent mechanical contraction via muscle ac-
tion potentials. In physiological conditions, a bunch of
nerve impulses (about 50 Hz) stimulates release of a large
amount of ACh from presynaptic nerve endings; as the
neurotransmitter, ACh produces trains of postsynaptic
membrane potentials and endplate action potentials, lead-
ing to tonic muscle contraction. ACh in the synaptic cleft
(gap) is rapidly hydrolyzed by AChE, causing a rapid de-
crease in the ACh level to that before ACh release and
subsequently terminates the role of ACh timely and effect-
ively. This rapidly repolarizes the postsynaptic membrane
potential for responding to the next release of ACh
(Martin 2005). The attenuation of 50-Hz or 100-Hz tonic
stimulation is resulted from blockade of presynapticTable 2 Effects of vecuronium on the amplitude of endplate p





Control 32.4 ± 3.3 32.2
0.5 32.3 ± 3.4 31.7
1.0 31.5 ± 3.2 27.4
2.0 33.1 ± 3.4 22.4 ±
4.0 32.7 ± 3.1 18.4 ±
* P < 0.05, ** P < 0.01, compared with the corresponding group without vecuronium
Data shown are means ± SEM.receptors. There are two types of vesicles for presynaptic
release of ACh: immediate release vesicles and storage
vesicles. Under the tonic stimulation of 50 Hz or 100 Hz,
ACh immediate-release vesicles are empty while ACh is
continuously transported from storage vesicles, leading to
decreases in ACh levels, EPP amplitudes, and rundown
rates of EPP trains. These in turn result in feedback regu-
lation of ACh, which maintains normal physiological func-
tion by preventing EPP rates from further decreases
(Bowman 1990). In the present study, we examined the
presynaptic effects of rocuronium and vecuronium based
on the initial attenuation of trains of EPPs caused by 50-
Hz tonic stimulation.
In the neuromuscular junction, ACh in the synaptic cleft
can play a positive or negative role in the feedback
regulation of ACh release from nerve terminals via the ac-
tion on presynaptic nAChRs (Fagerlund & Eriksson 2009;
Wessler 1989). More specifically, ACh at low or physio-
logical concentrations plays a positive feedback role in ACh
release, leading to increased immediate-release vesicles
transferred from storage vesicles in the nerve endings. The
positive feedback mechanism allows nerve-muscle tissues
to adapt to high-frequency stimulation (> 1 Hz) (Bowman
1980). In contrast, ACh at high concentrations plays a nega-
tive feedback role in ACh release, leading to depolarization
of the nerve terminals. These two feedback mechanisms
may affect the onset of actions of non-depolarizing muscle
relaxants to a certain extent. The non-uniform stretched
muscle preparation from the isolated rat phrenic nerveotentials (EPPs) in the isolated rat phrenic nerve
nt
EPP (mV) at different times after treatment
in 5 min 10 min
± 3.3 31.4 ± 3.2 31.2 ± 2.9
± 2.9 30.6 ± 3.3 29.7 ± 2.2
± 2.7 22.4 ± 2.8* 16.4 ± 2.1**##
3.3*# 14.4 ± 1.4**## 12.4 ± 1.3**##
3.3**## 12.4 ± 1.5**## 8.4 ± 1.3**##
; # P < 0.05, ## P < 0.01, compared with the control at the same time point; n = 5.
Table 3 Changes in string initial rundown rates of endplate potentials (EPPs) before and after treatment of the
isolated rat phrenic nerve diaphragm preparation with rocuronium or vecuronium
Drug (μg/ml) Before treatment 3 min after treatment 5 min after treatment
M1 MX R (%) M1 MX R (%) M1 MX R (%)
Rocuronium 2.5 46 ± 11 34 ± 10 26 46 ± 10 28 ± 10 40* 45 ± 12 26 ± 10* 42*
Vecuronium 0.5 46 ± 11 33 ± 11 28 46 ± 11 31 ± 10 33 45 ± 12 29 ± 11* 37*
* P < 0.05, compared with the corresponding group without drug treatment; n = 5. M1, the first quantum content of EPP; MX, the 11 to 55 average quantum
content of EPP; R, the rundown rate. M = Vc/q; Vc is the corrected amplitude of EPP and q is the quantum size of the MEPP. Data shown are means ± SEM.
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and miniature EPPs (Zou & Liu 1988). Using this approach,
we recorded an average of 30 mV of EPP.
There are two types of rundown: intratrain rundown
(reduction in the EPP size from one train to the next),
which is frequency-dependent, and intertrain rundown
(reduction in the EPP size within a train), which is rela-
tively independent of stimulation frequency during inter-
mittent stimulation (Moyer & van Lunteren 1999). The
initial rundown (intratrain rundown) of the EPP amplitude
usually decreases quickly within a train but recovers
almost completely from train to train during intermittent
stimulation. In the present study, administration of ro-
curonium or vecuronium decreased both intratrain run-
down and intertrain rundown of EPPs.
While most neuromuscular blocking agents act on post-
synaptic nicotinic receptors at the neuromuscular junction,
several lines of evidence also suggest a presynaptic role of
rocuronium and vecuronium. The impact of rocuronium
on the EPP initial rundown is related to the frequency of
stimulation: the higher stimulus frequency, the more initial
rundown. This feature indicates that rocuronium may have
a potent presynaptic effect (Feldman & Khaw 1995). This
is supported by the presynaptic effect of vecuronium
(Schwarz et al. 1985). In addition, using the isolated human
forearm, England and co-workers have demonstrated that
rocuronium produces non-depolarizing blockade in a man-
ner different from other non-depolarizing muscle relaxants
in terms of onset and/or recovery (England et al. 1996),
suggesting that rocuronium exerts a presynaptic effect.
Further, more directly, rocuronium binds to the presynap-
tic N-cholinergic receptors at the neuromuscular junction,
leading to presynaptic inhibition (Meistelman et al. 1992;
Feldman & Hood 1994).
Both rocuronium and vecuronium enhances ACh
release from presynapses. Compared to vecuronium,
rocuronium acts on EPP amplitudes with slightly greater
efficacy and faster onset, but smaller potency. It is spec-
ulated that rocuronium has faster and greater presynap-
tic inhibition (Li & Zhang 2004). The inhibitory effects
of the drugs on the initial rundown of EPP amplitudes
indicate that presynaptic inhibition by rocuronium may
be related to the direct effect on presynaptic nAChRs,
leading to reduced transport of neurotransmitters in
presynapses.Of note, sensitivity to rocuronium and/or vecuronium
may vary in certain medical conditions interfering with
neurotransmission at the neuromuscular junction. For in-
stance, patients with myasthenia gravis, an autoimmune
disorder involving the destruction of AChRs at the post-
synaptic membrane at the neuromuscular junction, are
hypersensitive to nondepolarizing neuromuscular blocking
drugs such as vecuronium, which can make the character-
istic symptoms such as fatigue worse (Itoh et al. 2002).
Similarly, patients with neuromyotonia, a disorder of
hyperexcitability of the peripheral nerve and characterized
by both myokymic and neuromyotonic discharges, also
exhibit increased sensitivity to the neuromuscular effects
of rocuronium (Ginsburg et al. 2009). Thus, lower doses
of rocuronium/vecuronium should be administered for
anesthesia in patients with these disorders.
In conclusions, both rocuronium and vecuronium en-
hance initial rundown of EPP amplitudes in the isolated
phrenic nerve diaphragm preparation of rats, suggesting
that both drugs produce significant presynaptic inhib-
ition. Compared to vecuronium, rocuronium is slightly
greater in efficacy and faster in onset, but smaller in po-
tency of blocking the neuromuscular junction.
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